Loading…
Loading…
Dick's Sporting Goods (NYSE:DKS) is plunging 25.3% to trade at $134.03, after the sporting-goods retailer's fiscal second-quarter earnings and revenue fell short of Wall Street's targets.
VGMS is a diversified bond ETF, focusing on corporate bonds. The portfolio is roughly evenly divided between investment and non-investment grade, leaning short-term, with a duration of 3.7 years. Unlike most Vanguard funds, VGMS is active. It could and has outperformed its benchmark since inception, only since last year.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanf.
FIX's record backlog, technology demand and Modular expansion support strong growth, but tougher comparisons may slow momentum.
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA study enrollment underway NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the company's investigational, oral, brain-penetrant selective inhibitor of mutant IDH1. "People with IDH1-mutant glioma urgently need additional treatment options.
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026 AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of idiopathic pulmonary fibrosis. Fast Track designation is an FDA process intended to facilitate the development and expedite the review of new drugs or biologics that treat serious conditions and address an unmet medical need.
Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 revenues up 23% to $18.5M and positive EBITDA. DERM's Emrosi franchise is gaining traction, with prescribers rising over 40% quarter-over-quarter and formulary coverage improving from 34% to 38%. Cost discipline is evident as SG&A declined and operating expenses rose less than 1%, while Emrosi's ASP and market penetration are expected to improve further.
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatment of solid tumors that are resistant to immune checkpoint inhibitors (ICIs).